Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.

NCT00256048 | Completed

• 1 other identifier: 2002.228
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine if naso-jejunal feeding (feeding beyond the stomach) improves the efficacy of enteral feeding (feeding into the gut) in critically ill patients. The study hypothesis is that in patients who fail to establish enteral feeding via the nasogastric route, introduction of nasojejunal feeding will lead to more effective enteral feeding than the current regime involving staged introduction of promotility agents.

Conditions

Critically Ill

Outcome Measures

Primary Outcomes (1)

• Efficacy of feeding

  participants will be followed until death, discharge from ICU, commencement of oral or parental nutrition or 28 days post ICU admission

Secondary Outcomes (2)

• 1. To determine the incidence of complications with enteral feeding via nasogastric and nasojejunal routes.

  participants will be followed until death, discharge from ICU, commencement of parental or oral nutrition or 28 days post ICU admission.

• 2. To assess the efficacy of current strategies for optimising enteral feeding efficacy.

  participants will be followed until death, discharge from ICU commencement of oral or parental nutrition,or 28 days post ICU admission.

Study Arms (2)

Standard Care

NO INTERVENTION

Patients will receive enteral nutrition via a nasogastric tube as per standard feeding regime

Nasojejunal Arm

ACTIVE COMPARATOR

Patient will receive feeding via a nasojejunal feeding tube

Procedure: Nasojejunal feeding

Interventions

Nasojejunal feeding PROCEDURE

Nasojejunal Arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult patients (18years or over) admitted to the ICU with an expected stay of more than 48 hours.
• Patients commenced on enteral feeding via a nasogastric tube who fail to tolerate gastric feeding due to excessive gastric aspirate volumes.

You may not qualify if:

• patients less than 18 years of age.
• Patients with known allergy to promotility agents, metoclopramide or erythromycin.
• Patients with a contra indication to nasojejunal feeding. -

Sponsors & Collaborators

• Melbourne Health: lead

Study Sites (1)

Intensive Care Unit, Royal Melbourne Hospital, Grattan Street

Parkville, Victoria, 3050, Australia

Location

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Megan Robertson

  Intensive Care Unit, Royal Melbourne Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 17, 2005
• First Posted: November 21, 2005
• Study Start: May 1, 2003
• Study Completion: July 1, 2005
• Last Updated: April 12, 2017

Record last verified: 2015-04

Locations

AU (1)